21 May 2013 - 21 May 2013 - Swedish pharma company Medivir AB (STO:MVIR B) unveiled today promising Phase Ia data for the investigational cathepsin K inhibitor MIV-711 for the treatment of osteoarthritis and osteoporosis.

Findings demonstrated that single doses of MIV-711 were safe and well tolerated in healthy subjects and showed linear pharmacokinetics over the investigated dose range (20 – 600 mg). Further, serum levels of the bone resorption biomarker CTX-I were suppressed in a dose dependent manner with up to 79% reduction at 24 hours after dose.

Medivir's EVP Development Charlotte Edenius said that the compound is currently in a Phase Ib multiple ascending dose study for up to four weeks, which is expected to provide the company with additional information on the pharmacological effects on both bone and cartilage turnover.

Data were presented at the European Calcified Tissue Society (ECTS) Annual Meeting in Lisbon.